The addition of Peregrine builds on Klick’s market access execution capabilities.
Klick Health announced its acquisition of market access strategy and value communications specialist Peregrine Market Access. This move is part of Klick’s ongoing efforts to build out its life sciences commercialization offerings.
Klick Health co-founder and chairman Leerom Segal commented in a press release, “Peregrine is a remarkable business with a sterling reputation and deep, trusted client relationships, making them the perfect accelerant to our growing market access business. Both Peregrine and Klick are passionate about helping clients get innovative therapies to the patients who need them; we believe this will be a greater challenge for patients in the future, which makes an investment in this area so valuable.”1 He also cited similarities in how both companies grew up fiercely independent in the industry.
John Guarino, founder and CEO of Peregrine Market Access, echoed those sentiments in the same release. “It has been great getting to know Leerom, the Klick leadership team, and Klick’s depth of expertise in medical, analytics, and AI,” he said. “Together, we will immediately be able to bring new innovations to clients and redefine what’s possible in market access strategy, analytics, and communications.”1 With this acquisition, there will be around 250 PhD/advanced degree professionals total in their internal Klick mediverse.
The financial details of this acquisition have not been disclosed.
Klick spent much of 2024 expanding their ongoing investment in the increasingly important value, access, and reimbursement segments within life sciences commercialization. They added a total of 40 new senior leaders across its client services, creative, growth, media, medical, and strategy teams to support its ongoing double-digit growth.2,3 The company has reported this growth for 27 years and counting. These teams span across North America, Singapore, and the UK. Also in 2024, it launched its free KlickRx ChatGPT plugin, which gives life sciences professionals the ability to easily and quickly obtain information within ChatGPT on industry payments to healthcare professionals in the US.
In early July of 2024, the company named former Publicis chief digital officer Ray Rosti as its new president.4 Chief operating officer Greg Rice said that Rosti’s extensive experience and leadership in digital and healthcare marketing over the past 25 years is what makes him an exceptional addition to the team.
Another recent piece to their market access puzzle was the 2023 addition of Ellen Cappellino, a former AstraZeneca and Vertex Pharmaceuticals executive with over 25 years of commercial experience within the industry, to the team. Now serving as Klick’s executive director of value, access, and reimbursement, Cappellino worked across the continuum of primary and specialty care therapeutic areas, including oncology and rare disease. Klick chief medical officer Holly Henry said about Cappellino, “We are excited that Ellen has joined our growing market access team…She has impeccable scientific credentials and deep experience working in the value space, and she’s a wonderful complement to our existing team.” 5
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.